{
    "clinical_study": {
        "@rank": "41974", 
        "arm_group": {
            "arm_group_label": "Florbetapir F-18 for Parkinson's Disease", 
            "arm_group_type": "Experimental", 
            "description": "This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.\nEach evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this protocol is to investigate the monoaminergic\n      (dopamine\u3001serotonin\u3001and norepinephrine ) nervous system and amyloid deposition in\n      Parkinson's disease patients with non-motor symptoms (focus on impulse control disorders and\n      dementia) by novel 18F-DTBZ and Florbetapir F-18 PET imaging.\n\n      This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and\n      monoaminergic function by18F- DTBZ PET in NC group, PD group, PDD group, AD group.\n\n      Investigators will also analyze monoaminergic function by18F- DTBZ PET in PDI group."
        }, 
        "brief_title": "Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "detailed_description": {
            "textblock": "Study duration is expected to be completed in a period of 3 year. This study will compare\n      the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function\n      by18F- DTBZ PET in 10 age-matched healthy subjects (NC group), 30 PD patients without\n      dementia/ICD (PD group), 30 PD  patients with dementia (PDD group), and 20 patients with\n      dementia (AD group). We will also analyze monoaminergic function by18F- DTBZ PET in 30 PD\n      patients with ICD (PDI group).\n\n      Each evaluable subject involved in this study must fulfill all the inclusion and exclusion\n      criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will\n      have 4 visits in this study ,as one screening visit, one florbetapir F-18 imaging visit, one\n      18F-DTBZ imaging visit, and one safety evaluation.PDI patients will have 3 visits in this\n      study, as one screening visit, one 18F-DTBZ imaging visit, and one safety evaluation. Safety\n      measurement will be evaluated by medical history, vital signs, physical examinations,\n      laboratory examinations and collecting of adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.10 healthy subjects : i. Male or female subjects, age range 20~80. ii. Subjects have no\n        known neurological or psychiatric disease. However, mild peripheral neuropathies, such as\n        entrapment syndrome or sciatica are allowed.iii. Subjects who provide a written informed\n        consent prior to study entry.\n\n        2.30 subjects with a diagnosis of PD : i. Male or female patients, age range 20~80. ii.\n        Patients should be fulfilled \"UK Parkinson's Disease Society Brain Bank Clinical\n        Diagnostic Criteria\" as \"PD\". (Appendix I).iii. Patients should not have any clinical\n        evidence of dementia or ICD. iv. Patients who provide a written informed consent prior to\n        study entry. If the patient is incapable of informed consent, the caregiver may consent on\n        behalf of the patient (the patient must still confirm assent).\n\n        3.30 subjects with a diagnosis of PD with dementia : i. Male or female patients, age range\n        20~80.ii. Patients should be fulfilled the \"Movement Disorders Society diagnostic criteria\n        of PDD as \"possible\" or \"probable\" PDD (Emre, 2006). (Appendix II) iii. Patients who\n        provide a written informed consent prior to study entry. If the patient is incapable of\n        informed consent, the caregiver may consent on behalf of the patient (the patient must\n        still confirm assent).iv. Patients who provide a written informed consent prior to study\n        entry. If the patient is incapable of informed consent, the caregiver may consent on\n        behalf of the patient (the patient must still confirm assent).\n\n        4.20 subjects with a diagnosis of AD : i. Male or female patients, age range 20~80. ii.\n        Patients should be fulfilled the \"DSM-IV-TR Diagnostic criteria for Alzheimer's Disease\"\n        as AD. (Appendix III).iii. Patients who provide a written informed consent prior to study\n        entry. If the patient is incapable of informed consent, the caregiver may consent on\n        behalf of the patient (the patient must still confirm assent).iv. Patients who provide a\n        written informed consent prior to study entry. If the patient is incapable of informed\n        consent, the caregiver may consent on behalf of the patient (the patient must still\n        confirm assent).\n\n        5.30 subjects with a diagnosis of PD with ICD : i. Male or female patients, age range\n        20~80. ii. Patients should be fulfilled one of the diagnostic criteria or definition in\n        these ICDs: pathological gambling, hypersexuality, compulsive shopping, compulsive eating,\n        punding, and compulsive medication use (Voon, 2009). (Appendix IV).iii. Patients who\n        provide a written informed consent prior to study entry. If the patient is incapable of\n        informed consent, the caregiver may consent on behalf of the patient (the patient must\n        still confirm assent).iv. Patients who provide a written informed consent prior to study\n        entry. If the patient is incapable of informed consent, the caregiver may consent on\n        behalf of the patient (the patient must still confirm assent).\n\n        Exclusion Criteria:\n\n          1. Pregnant or becoming pregnant during the study (as documented by pregnancy testing at\n             screening or at any date during the study according to the PI discretion) or current\n             breast feeding.\n\n          2. Any subject who has a clinically significant abnormal laboratory values, and/or\n             clinically significant or unstable medical or psychiatric illness.\n\n          3. History of drug or alcohol abuse within the last year, or prior prolonged history of\n             abuse.\n\n          4. History of intracranial operation, including thalamotomy, pallidotomy, and/or deep\n             brain stimulation.\n\n          5. Any documented abnormality in the brain by CT or MRI of brain, which might contribute\n             to the motor function, such as hydrocephalus, multiple infarction and\n             encephalomalacia, will be excluded. Mild cortical atrophy and non-specific white\n             matter changes will be allowed.\n\n          6. Any evidence of secondary parkinsonism (multiple infarcts, intoxication, and\n             hydrocephalus, etc) or other neurodegenerative diseases (multiple system atrophy,\n             progressive supranuclear palsy).\n\n          7. History of allergy to radioligands that contain 18F isotope."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039024", 
            "org_study_id": "100-4356A"
        }, 
        "intervention": {
            "arm_group_label": "Florbetapir F-18 for Parkinson's Disease", 
            "description": "During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.\nDuring this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.\nThe proposed dose for this study is based on our phase I study.  At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem.  The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010).", 
            "intervention_name": "Florbetapir F-18", 
            "intervention_type": "Drug", 
            "other_name": "Florbetapir F-18"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "18F-DTBZ", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "last_name": "Yi-Hsin Weng", 
                "phone": "+886 975365693"
            }, 
            "facility": {
                "address": {
                    "city": "Taoyuan", 
                    "country": "Taiwan", 
                    "zip": "333"
                }, 
                "name": "Chang Gung Memory Hospital"
            }, 
            "investigator": {
                "last_name": "Yi-Hsin Weng", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET", 
        "overall_contact": {
            "email": "yhweng@adm.cgmh.org.tw", 
            "last_name": "Yi-Hsin Weng", 
            "phone": "+886 3-3281200", 
            "phone_ext": "8412"
        }, 
        "overall_official": {
            "affiliation": "Chang Gung Memory Hospital", 
            "last_name": "Yi-Hsin Weng", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in NC group, PD group, PDD group, AD group.\nDuring this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging.", 
            "measure": "To compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039024"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chang Gung Memorial Hospital", 
            "investigator_full_name": "NJI90OKM", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chang Gung Memorial Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Science Council, Taiwan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chang Gung Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}